Skip to main content

Pyxis Oncology, Inc.

corporate_fare Company Profile

Pyxis Oncology, Inc.

PYXS·NASDAQ·Life Sciences·CIK 0001782223

Pyxis Oncology is a clinical-stage oncology company focused on developing treatments for solid tumors, specifically head and neck squamous cell carcinoma (HNSCC). The company's main product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate (ADC). MICVO targets extradomain-B of fibronectin (EDB+FN), a specific variant of fibronectin found in the extracellular matrix (ECM) within the tumor microenvironment (TME). EDB+FN is an isoform of fibronectin that is highly expressed in various solid tumors but negligibly expressed in normal adult tissues. This protein contributes to cancer progression by promoting cell proliferation, adhesion, and migration, activating integrin signaling, stimulating angiogenesis and vascular remodeling, driving epithelial-mesenchymal transition (EMT), and establishing pre-metastatic niches. MICVO is composed of a fully human IgG1 monoclonal antibody linked to an optimized auristatin (Aur0101) microtubule inhibitor payload via a cleavable linker. Unlike traditional ADCs that bind to antigens on cancer cell surfaces, MICVO is designed to bind to EDB+FN in the tumor ECM. Extracellular proteases in acidic conditions cleave the linker, releasing the Aur0101 payload. This payload then diffuses into cancer cells, directly killing them. The dying cancer cells release the payload, which then diffuses into nearby cancer cells, killing them through a bystander effect. Additionally, the dying cancer cells release neoantigens, triggering immunogenic cell death (ICD). This three-pronged mechanism of action is believed to offer improved stability and anti-tumor activity compared to conventional ADCs.

Pyxis Oncology, Inc. (NASDAQ:PYXS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for PYXS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for PYXS spans 8-K, 10-Q, DEF 14A, PRE 14A.

Recent high-impact activity:

  • Pyxis MICVO Data Mature: 39% cORR, 9.2-Month mDOR, 81% 12-Month OS in 2L+ HNSCC
  • MICVO Response Rate Rises to 39% as Pyxis Plots Mid-2027 Phase 3
  • Pyxis Doubles Authorized Shares to 380M After Stockholder Vote
  • Pyxis Q3 Loss Narrows to $20.0M; Going Concern Warning Lifted, Runway to 1H 2028
  • Pyxis Q3 Loss Narrows to $20.0M; Cash Runway Extended Into 1H 2028

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$13.86M
Net Income
-$79.62M
Diluted EPS
-$1.28
Op. Cash Flow
-$63.5M
Free Cash Flow
-$63.51M
Gross Profit
$11.47M
Operating Income
-$84.42M
Cash & Equivalents
$15.42M
Debt / Equity
0.00×
Net Margin
-5.75×
Shares Outstanding
62.69M sh
Source: 10-K · filed 2026-03-23 · accession 0001193125-26-118532

Short Interest & Short Volume

5.82 days to cover

FINRA reported short interest of 4,525,205 shares in PYXS as of the October 30, 2026 settlement, a 4.1% increase from the prior period — about 5.8 days to cover at its recent average daily volume. On November 20, 2026, 40.8% of PYXS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,525,205 shares as of October 30, 2026
Change vs prior period▲ 4.1%
Days to cover5.82 at avg daily volume of 777,619
Daily short volume (FINRA facilities)40.8% of 1,608,542 shares on November 20, 2026
5-day average short volume42.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for PYXS, detected from its recent SEC filings · based on capital-structure filings through 2026-11-13.

1 recent capital raiseATM program1 shelf registration

Authorized Shares Doubled to 380M · Large Potential Dilution Headroom

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with P →
$1.81
52-week range · as of 2026-11-19 $1.03 – $5.55
Market cap
$216.49M
Volume
3.1M (3.3× avg)
3-mo avg 925.5K
Live data · 2026-11-21 14:50 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PYXS - Latest Insights

PYXS
Nov 19, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.81 info
Change: +$0.310 (+21%) info
Market Cap: $216.49M info
PYXS
Nov 18, 2026, 6:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $1.81 info
Change: +$0.350 (+24%) info
Market Cap: $216.49M info
PYXS
Nov 13, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $1.81 info
Change: +$0.230 (+15%) info
Market Cap: $216.49M info
PYXS
Nov 05, 2026, 7:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.65
Real-time Price: $1.81 info
Change: +$0.160 (+10%) info
Market Cap: $216.49M info
PYXS
Nov 05, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $1.81 info
Change: +$0.160 (+10%) info
Market Cap: $216.49M info
PYXS
Nov 05, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $1.81 info
Change: +$0.160 (+10%) info
Market Cap: $216.49M info
PYXS
Oct 21, 2026, 4:27 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $1.79
Real-time Price: $1.81 info
Change: +$0.020 (+1%) info
Market Cap: $216.49M info
PYXS
Oct 09, 2026, 5:08 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $2.03
Real-time Price: $1.81 info
Change: -$0.220 (-11%) info
Market Cap: $216.49M info
PYXS
Oct 02, 2026, 8:35 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $2.21
Real-time Price: $1.81 info
Change: -$0.400 (-18%) info
Market Cap: $216.49M info
PYXS
Oct 01, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.20
Real-time Price: $1.81 info
Change: -$0.3901 (-18%) info
Market Cap: $216.49M info
PYXS
Oct 01, 2026, 9:30 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $2.33
Real-time Price: $1.81 info
Change: -$0.520 (-22%) info
Market Cap: $216.49M info
PYXS
Sep 30, 2026, 1:11 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.63
Real-time Price: $1.81 info
Change: -$0.8215 (-31%) info
Market Cap: $216.49M info
PYXS
Sep 29, 2026, 4:56 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $2.76
Real-time Price: $1.81 info
Change: -$0.945 (-34%) info
Market Cap: $216.49M info
PYXS
Sep 29, 2026, 4:24 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.67
Real-time Price: $1.81 info
Change: -$0.860 (-32%) info
Market Cap: $216.49M info
PYXS
Sep 09, 2026, 1:42 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $3.50
Real-time Price: $1.81 info
Change: -$1.69 (-48%) info
Market Cap: $216.49M info
PYXS
Sep 09, 2026, 7:34 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.10
Real-time Price: $1.81 info
Change: -$1.29 (-42%) info
Market Cap: $216.49M info
PYXS
Sep 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.14
Real-time Price: $1.81 info
Change: -$2.33 (-56%) info
Market Cap: $216.49M info
PYXS
Sep 08, 2026, 7:39 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.89
Real-time Price: $1.81 info
Change: -$2.08 (-53%) info
Market Cap: $216.49M info
PYXS
Sep 02, 2026, 2:42 AM EDT
Source: ShareCast
Importance Score:
9
Price at Filing: $3.41
Real-time Price: $1.81 info
Change: -$1.60 (-47%) info
Market Cap: $216.49M info
PYXS
Aug 13, 2026, 7:44 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.32
Real-time Price: $1.81 info
Change: -$1.51 (-45%) info
Market Cap: $216.49M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets